<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02232360</url>
  </required_header>
  <id_info>
    <org_study_id>STAFENO</org_study_id>
    <nct_id>NCT02232360</nct_id>
  </id_info>
  <brief_title>Effects of Combined Therapy With Statin Plus Fenofibrate on Coronary Atherosclerotic Plaque Compared With Statin Alone</brief_title>
  <official_title>The Comparative Analysis of the Effects on Plaque Volume and Tissue Characteristics Between Combined Therapy With STAatin Plus FENOfibrate and Statin Alone in Mild to Moderate, Non- Intervened Coronary Artery Stenosis (STAFENO Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gachon University Gil Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine effects of combination therapy with rosuvastatin
      and fenofibrate on atheromatous plaques and its tissue characteristics of de novo coronary
      lesions with intermediate stenosis in patient with coronary artery disease, compared with
      rosuvastatin alone therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease remains the leading cause of morbidity and mortality worldwide. In the
      past few decades, optimal pharmacological therapies with statins targeting LDL-cholesterol
      substantially reduce the risks of cardiovascular disease. However, the residual
      cardiovascular risk is still high, requiring need for additional preventive therapies to
      achieve even greater risk reduction.

      Recent meta-analysis demonstrated fibrates can reduce the risk of coronary events and might
      have a role in patients with high cardiovascular risks or combined dyslipidemia. Likewise,
      fenofibrate had a possible benefit for patients with high triglyceride level and low
      HDL-cholesterol level in the post-hoc analysis of ACCORD or FIELD trials.

      Thus, investigators tried to determine effects of combination therapy with rosuvastatin and
      fenofibrate on atheromatous plaques and its tissue characteristics of de novo coronary
      lesions with intermediate stenosis in patient with coronary artery disease, compared with
      rosuvastatin alone therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute changes of Necrotic Core volume</measure>
    <time_frame>After 12±2 months treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute and percent changes of area of necrotic core, dense calcium, fibrofatty, fibrous plaque</measure>
    <time_frame>After 12±2 months treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of thin-cap fibroatheroma</measure>
    <time_frame>After 12±2 months treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and percent changes of volume/area of external elastic membrane, lumen, plaque</measure>
    <time_frame>After 12±2 months treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remodeling index</measure>
    <time_frame>After 12±2 months treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular events (MACE)</measure>
    <time_frame>After 12 months treatment</time_frame>
    <description>The composites of all-cause death, non-fatal myocardial infarction, stroke, culprit lesion revascularization, or non-culprit lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug events</measure>
    <time_frame>After 12±2 months treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatine phosphokinase</measure>
    <time_frame>After 12±2 months treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change of Necrotic core volume</measure>
    <time_frame>After 12±2 months treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin and fenofibrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy: rosuvastatin 10 mg and fenofibrate 160 mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin 10 mg per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin and fenofibrate</intervention_name>
    <description>Combination therapy: rosuvastatin 10 mg and fenofibrate 160 mg per day</description>
    <arm_group_label>Rosuvastatin and fenofibrate</arm_group_label>
    <other_name>Combination therapy with rosuvastatin and fenofibrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin alone</intervention_name>
    <description>Rosuvastatin 10mg per day</description>
    <arm_group_label>Rosuvastatin alone</arm_group_label>
    <other_name>Rosuvastatin alone therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with coronary artery disease who were 20 years of age or older and needed
             coronary angiography

          -  Intermediate coronary artery stenosis (diameter stenosis ≥30% to ≤60% by visual
             estimation, diameter ≥2.0 mm to ≤4.0 mm, de novo lesion in native coronary artery) in
             which virtual histology-intravascular ultrasound (VH-IVUS) could be feasible

          -  Combined dyslipidemia

               -  Stain-naive patients - LDL-cholesterol ≥70 mg/dL and non-HDL-cholesterol ≥130
                  mg/dL

               -  Patients taking statin within 2 weeks - LDL-cholesterol &lt; 100 mg/dL and
                  non-HDL-cholesterol ≥130 mg/dL

          -  Patients who gave written informed consent

        Exclusion Criteria:

          -  Diabetic patients

          -  Cardiogenic shock

          -  Heart failure with symptoms of New York Heart Association class III/IV or left
             ventricular ejection fraction &lt;35%

          -  Renal dysfunction (creatinine level ≥1.7 mg/dL or dependence of dialysis

          -  Hepatic dysfunction (transaminase level &gt; 3 times of normal within limit)

          -  Pregnancy or breast-feeding women

          -  Familial hypercholesterolemia

          -  Hypertriglyceridemia (triglyceride level &gt;500 mg/dL)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung Hwan Han, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gachon University Gil Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seung Hwan Han, MD</last_name>
    <phone>82-32-460-3054</phone>
    <email>shhan@gilhospital.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pyung Chun Oh, MD</last_name>
    <phone>82-32-460-3054</phone>
    <email>likemed@gilhospital.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Konyang University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jang Ho Bae, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jang Ho Bae, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Medical School and Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Joon Hong, MD</last_name>
    </contact>
    <investigator>
      <last_name>Young-Joon Hong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University ilsanPaik Hospital</name>
      <address>
        <city>Ilsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Yoon Lee, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sung Yoon Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Hwan Han, MD, PhD</last_name>
      <phone>82-32-460-3054</phone>
      <email>shhan@gilhospital.com</email>
    </contact>
    <investigator>
      <last_name>Seung Hwan Han, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang-Wook Kim, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sang-Wook Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National Univesity Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sang Hyun Kim, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sang Hyun Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2014</study_first_submitted>
  <study_first_submitted_qc>September 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2014</study_first_posted>
  <last_update_submitted>August 22, 2016</last_update_submitted>
  <last_update_submitted_qc>August 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gachon University Gil Medical Center</investigator_affiliation>
    <investigator_full_name>Seung Hwan Han</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Atherosclerotic plaque</keyword>
  <keyword>Virtual histology intravascular ultrasound</keyword>
  <keyword>Plaque composition</keyword>
  <keyword>Rosuvastatin</keyword>
  <keyword>Fenofibrate</keyword>
  <keyword>Coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

